Abstract: Age-related decline in serum testosterone and dehydroepiandrosterone sulfate concentrations occur in men. Low concentrations of these endogenous androgens have been linked with insulin resistance, which is an important upstream driver for metabolic abnormalities such as hyperglycemia, hypertension, or hyperlipidemia, and increased cardiovascular risk. Moreover, men with diabetes have significantly less circulating androgen than nondiabetic men. Here, we summarize how androgen affects insulin resistance and atherosclerosis in men with type 2 diabetes. Low serum concentrations of endogenous androgens are associated with visceral fat accumulation. Androgen deprivation by castration to treat prostate cancer increases insulin resistance, while testosterone administration in type 2 diabetic men with androgen deficiency improves glucose homeostasis and decreases visceral fat, in addition to alleviating symptoms of androgen deficiency including erectile dysfunction. Androgen correlates inversely with severity of atherosclerosis and has beneficial effects upon vascular reactivity, inflammatory cytokine, adhesion molecules, insulin resistance, serum lipids, and hemostatic factors. Because men with type 2 diabetes have relative hypogonadism, testosterone supplementation could decrease both insulin resistance and atherosclerosis.
INTRODUCTION
Serum testosterone and dehydroepiandrosterone sulfate (DHEA-S) concentrations decline in older men. Serum androgen concentrations are low during childhood, increasing at puberty until adult concentrations are reached.
Beginning at approximately 25 years of age, serum testosterone concentrations then steadily decline by a mean of 1.0% per year. Serum DHEA-S concentrations decline to an even greater extent, by a mean of 2.3% per year [1] .
Overt hypogonadism alters body composition and affects mood, cognitive function, sexual function, bone mineral density, and several factors important for cardiovascular disease [2] . Decreased concentrations of testosterone also have been implicated in insulin resistance, which is an important upstream driver for metabolic abnormalities such as hyperglycemia, hypertension, or hyperlipidemia [3, 4] . In addition, low concentrations of testosterone are associated with increased risk of cardiovascular disease (CVD) in men [5] . Testosterone replacement in men with symptomatic androgen deficiency is indicated to improve quality of life, maintain lean body mass, preserve bone density, and protect against insulin resistance and atherosclerosis [6, 7] .
Men with diabetes have significantly lower plasma concentrations of free and total testosterone, as well as DHEA-S, than nondiabetic men [8, 9] . CVD is the leading cause of mortality and morbidity in patients with diabetes, who have 2 to 5 times the risk of CVD of the general population, partly because of decreased androgens. Here we summarize how androgen has been found to influence insulin resistance and atherosclerosis in men with type 2 diabetes.
RELATIONSHIPS BETWEEN SERUM TESTO-STERONE CONCENTRATIONS AND INSULIN RESISTANCE
We previously described six patients whose glycemic control was worsened by castration for treatment of prostate cancer, despite increased endogenous insulin secretion [10] . This finding suggested that decreased concentrations of testosterone might contribute importantly to insulin resistance.
Observational Studies
Low testosterone concentrations are expected in men with obesity because of increased conversion of testosterone to estrogen in adipose tissue by the enzyme aromatase, and also because of inhibition of the hypothalamicpituitary-gonadal axis by leptin [11] . On the other hand, low serum testosterone concentrations exacerbate obesity since sufficient testosterone acts at specific receptors to produce lipolytic effects in adipocytes [12] . As suggested by the above observations in therapeutic castration, low concentrations of free and total testosterone in men are associated with hyperinsulinemia [3, 4] . Compared to men with normal concentrations of total testosterone, men with low concentrations have significantly higher body mass index (BMI), waist/hip ratio, systolic blood pressure, fasting and postprandial plasma glucose concentrations, and fasting serum insulin and total cholesterol concentrations [3] . Results from the Massachusetts Male Aging Study suggest that low concentrations of testosterone may contribute to development of insulin resistance and subsequent type 2 diabetes [13] .
Insulin resistance is central to the metabolic syndrome, which has received increasing attention in the past few years as a concurrence of CVD risk factors including abdominal obesity, impaired glucose tolerance, dyslipidemia, and hypertension [14] . Patients with type 2 diabetes mellitus often show clustering of risk factors, which puts them at particularly high risk for CVD. Laaksonen et al. reported that independently of BMI, low serum testosterone concentrations were associated with not only individual components of the metabolic syndrome but also the metabolic syndrome itself [15] . Seidell et al. reported that serum free testosterone was associated negatively with visceral fat area [16] . Low serum testosterone concentrations, on the other hand, predict an increase in visceral fat and development of metabolic syndrome in middle-aged men [17, 18] . Patients with Klinefelter's syndrome, who have hypergonadtropic hypogonadism, have higher incidence of diabetes mellitus because of insulin resistance [19] .
Male patients with absence of estrogen reflecting aromatase deficiency show delayed skeletal maturation, osteopenia, and abnormal glucose and lipid metabolism [20] . Alternatively, estrogen receptor mutations can result in an estrogen resistance syndrome associated with increased fasting glucose concentrations and insulin resistance [21] . Physiologic actions of testosterone in men thus appear to be mediated in part by estrogen receptors following conversion to estrogen by site-specific aromatases in target tissues.
Interventional Studies

Clinical Studies
Treatment with testosterone was shown to increase lean body mass and decrease adipose mass by decreasing proteolysis and protein oxidation while increasing lipolysis and fat oxidation [22] . The role of testosterone in modulating the somatotropic axis and enhancing growth hormone (GH) secretion is well established [23] . Whether changes in lipolysis and fat oxidation brought about by testosterone therapy are caused by a testosterone effect alone or by a mechanism also involving GH remains unresolved. Testosterone also has been shown to decrease adipose tissue mass by increasing responsiveness to catecholamine-induced lipolysis through up-regulation of -adrenergic receptor density and postreceptor effects [24] .
Young men with high testosterone secretion have low visceral fat, while aging men with low testosterone have abdominal obesity. Testosterone treatment in the latter was followed by a reduction in visceral fat mass according to computed tomography [25] . Magnetic resonance imaging demonstrated that androgen therapy decreased visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (SAT), and the VAT/SAT ratio [26] . These effects were limited largely to men with low pretreatment testosterone concentrations.
Effects of androgen treatment on insulin sensitivity may be mediated by a change in body composition and by inhibition of lipoprotein lipase activity, resulting in reduced triglyceride uptake and accelerated triglyceride release from abdominal adipose tissue [27] . Reduction in adipose tissue also may decrease circulating free fatty acids, resulting in improvement in insulin sensitivity. Testosterone replacement given to men with symptomatic androgen deficiency resulted in reductions of serum tumor necrosis factor (TNF)-and interleukin (IL)-1 compared with placebo, as well as increase in IL-10 [28] . Most studies of effects of androgen replace-ment on cholesterol profiles show modest reduction of total cholesterol, LDL cholesterol, and HDL cholesterol, according to a recent meta-analysis [29] .
Effects of testosterone on insulin sensitivity remain controversial; some studies have suggested that physiologic testosterone replacement improves insulin sensitivity in middle-aged men with low testosterone [6, 7] . In contrast, administration of supraphysiologic doses of testosterone to castrated male rats [30] and of anabolic steroid to power lifters [31] has been shown to induce insulin resistance. We believe that both subphysiologic and supraphysiologic testosterone concentrations might adversely affect insulin sensitivity.
Oral testosterone treatment of type 2 diabetic men with androgen deficiency improves glucose homeostasis and body composition (decrease in visceral fat), and improves symptoms of androgen deficiency including erectile dysfunction [32] .
Maffei et al. reported that in a man with a mutation of the aromatase gene, estrogen treatment decreased extent of acanthosis nigricans, insulin resistance, and steatohepatitis, coupled with better glycemic control and disappearance of two carotid plaques [33] .
Deprivation
We have previously described six patients in whom glycemic control was worsened, in spite of increased endogenous insulin secretion, by castration for treatment of prostate cancer [10] . This finding suggested that decreased concentrations of testosterone might play an important role in insulin resistance. Inaba et al. similarly reported two patients who showed marked hyperglycemia after androgendeprivation therapy for prostate cancer [34] , but showed better glycemic control when given an insulin sensitizer, thiazolidinedione.
Smith et al. reported that gonadotropin releasing hormone (GnRH) agonists increased weight and percentage fat body mass while decreasing percentage lean body mass and muscle size in men with prostate cancer [35] . The increased adiposity resulted primarily from accumulation of subcutaneous rather than intraabdominal adipose tissue. In a few human studies, elderly men with hypogonadism induced with GnRH agonists developed significant increases in serum TNF-and IL-6 [36] .
Animal Studies
Castrated male rats have decreased insulin sensitivity that is improved by low-dose testosterone administration [30] . Both excessive and deficient testosterone appear to result in insulin resistance in the male rat. Castration of male mice was reported to increase the endogenous TNF-production elicited by administration of bacterial endotoxin; this response was suppressed by subsequent testosterone replacement [37] .
Male aromatase-knockout mice appear to develop glucose intolerance and insulin resistance. Treatment of such mice with estrogen improved glucose metabolism [38] . Alternatively, male estrogen receptor-knockout mice result in marked increase in white adipose tissue, insulin resistance, impaired glucose tolerance, and altered energy metabolism [39] .
RELATIONSHIPS BETWEEN SERUM DEHYDRO-EPIANDROSTERONE SULFATE CONCENTRATION AND INSULIN RESISTANCE
DHEA and its sulfate ester DHEA-S together represent the most abundant adrenally produced steroid, a weak androgen contributing to androgenicity mainly after peripheral conversion to more potent androgens, testosterone and dihydrotestosterone. DHEA-S, which is converted to the active form DHEA in a linear manner, represents the circulating hormonal pool of DHEA and is a good marker for DHEA availability.
Increasing evidence suggests that DHEA may have a number of clinical uses. After passage of the US Dietary Supplement Health and Education Act of 1994, DHEA became widely available, finding a growing popular market as a "fountain of youth" or "super hormone" expected to prevent cancer, heart disease, and type 2 diabetes; to delay aging; to prevent or slow progression of Alzheimer's disease; to boost libido; and to alleviate autoimmune disease [40] .
Men with diabetes have significantly lower plasma concentrations of DHEA than nondiabetic men [9, 41] . Decreased DHEA and DHEA-S concentrations in patients with type 2 diabetes are associated with low activity of 17, 20-lyase, an adrenal steroidogenic enzyme [41] . Increased risk for CVD in diabetic men could be mediated in part by low concentrations of DHEA.
Observational Studies
Low DHEA concentrations are associated with development of central obesity [42] , while decreased serum concentrations of DHEA may contribute to insulin resistance [43] . Epidemiologic studies linking low serum DHEA concentrations with conditions characterized by insulin resistance and hyperinsulinemia offer additional supportive evidence [44] .
Conversely, insulin may reduce serum concentrations of DHEA and DHEA-S by both inhibiting their production and promoting their clearance [45] . Experimentally induced hyperinsulinemia lowers serum adrenal androgens [46] . Administration of metformin is reported to increase serum DHEA-S secondarily to alleviation of hyperinsulinemia [47] . One factor responsible for the epidemiologically demonstrated association between hyperinsulinemia and atherosclerosis may be insulin-mediated suppression of serum DHEA and DHEA-S concentrations.
Interventional Studies
Clinical Studies
Villareal and Holloszy reported a significant increase in an insulin sensitivity index in response to DHEA in the elderly [48] . DHEA treatment can reduce body weight and serum TNF- [49] , and also may increase insulin sensitivity [43] and slow progression of type 2 diabetes [43] , although some studies have reported conflicting findings concerning effects of DHEA supplementation on insulin sensitivity [50, 51] .
Serum estradiol concentrations and free testosterone concentrations increase after DHEA administration, although not significantly [52] . Whether DHEA exerts its effects mainly by direct action or by peripheral bioconversion to androgens and estrogens remains an unsettled matter.
Animal Studies
DHEA, a precursor of both estradiol and testosterone, has been shown to have an antiobesity effect in several species. Administration of DHEA has been reported to reduce obesity [53] , hyperlipidemia, severity of diabetes [54] , and atherosclerosis [55] in obese rodents. Genetically diabetic (db/db) mice develop obesity and glucose intolerance associated with insulin resistance, and subsequently exhibit cell necrosis and islet atrophy. Supplementing their diet with DHEA prevented these pathologic changes and effected rapid remission of hyperglycemia, cell dysfunction, and insulin resistance [56] . Adiponectin gene expression in adipose tissue and serum adiponectin levels were elevated in DHEA-treated rats by activation of peroxisome proliferatorsactivated receptor (PPAR ) [57] .
RELATIONSHIPS BETWEEN SERUM TESTO-STERONE CONCENTRATION AND ATHERO-SCLEROSIS
We recently demonstrated a negative association between serum testosterone concentration and carotid atherosclerosis, determined by ultrasonographically evaluated intima-media thickness (IMT) and plaque score, in men with type 2 diabetes [58] . In addition, IMT and plaque score were significantly greater in patients with lower concentrations of free testosterone (<10 pg/ml) than in patients with higher concentrations of free testosterone.
Observational Studies
Low testosterone concentrations in men have been found to be associated with increased risk of CVD [59] . Significant negative correlations have been detected between serum testosterone concentration and measures of both extent and severity of coronary artery disease in angiographic studies [60] . A recent study from Denmark determined a relationship between low concentrations of testosterone and acute ischemic stroke, with total testosterone concentration showing inverse association with stroke severity, infarct size, and mortality [61] . However, other studies examining the association between low concentrations of testosterone and CVD mortality have been inconclusive. In disagreement with several reports suggesting that low concentrations of testosterone are associated with increased risk of CVD in men, some investigators have found no significant association between total testosterone concentration and prevalence of CVD [62] . Our own study found that serum testosterone concentrations did not differ significantly between patients with and without clinical CVD; however, serum free testosterone concentrations correlated negatively with ultrasonographically evaluated mean IMT and plaque score, which are early markers of atherosclerosis even prior to clinical manifestations. In the same study, the association of low free testosterone concentration with severity of carotid atherosclerosis was stronger than that observed for total testosterone concentration.
Testosterone exhibits a favorable effect upon vascular reactivity, inflammatory cytokine production, adhesion molecule expression, insulin resistance, serum lipid concentrations, and hemostatic factors [37] , although data concerning the relationship between androgens and lipids are to some extent contradictory. Cross-sectional studies have demonstrated a positive correlation between HDL cholesterol and testosterone, but inconsistent relationships between testosterone and total cholesterol, LDL cholesterol, and triglycerides [63] .
Men with diabetes have significantly lower plasma concentrations of free and total testosterone than nondiabetic men. Increased risk for CVD in diabetic men could be mediated partially through low concentrations of testosterone.
Interventional Studies
Clinical Studies
Short-term intracoronary testosterone administration at physiologic concentrations was found to induce coronary artery dilatation and increase coronary blood flow in men with established coronary artery disease [64] . In addition, short-term administration of intravenous testosterone improves exercise tolerance and reduces the angina threshold in men with coronary artery disease [65, 66] . Testosterone treatment enhances endothelium-dependent as well as endothelium-independent vasodilatation [67] . In addition, testosterone attenuates expression of vascular cell adhesion molecule (VCAM)-1 in human umbilical vein endothelial cells (HUVEC), thus inhibiting adhesion of monocytes to endothelial cells [68] . The last of the above effects is mediated by endothelial cell aromatase, which converts testosterone to estradiol. Estrogen may aid in maintenance of vascular function in men. A direct effect of estrogen on vascular cells has been demonstrated [69] . A male patient with estrogen deficiency showed marked impairment of endothelium-dependent vasodilatation of the brachial artery [70] , suggesting that low-dose estrogen might offer cardioprotection. Indeed, a low-dose estrogen regimen given to Finnish men with prostate cancer resulted in significant lowering of cardiovascular mortality [71] . In men, estrogens also may offer a degree of protection against CVD by influencing the lipid profile [72] . On the other hand, induced hypogonadism to treat prostate cancer increases augmentation of central arterial pressure, suggesting large-artery stiffening [73] .
Animal Studies
In an animal model, castration increased aortic atheroma formation while testosterone replacement ameliorated this effect [74] . Physiologic testosterone supplementation also has been shown to reduce atherosclerosis in orchidectomized LDL-receptor knockout mice fed a cholesterol-enriched diet [75] . Increased aortic lesion formation was reported in orchidectomized male mice, while a reduction in plaque development was demonstrated in orchidectomized mice receiving physiologic testosterone supplementation. This effect was not observed in animals treated simultaneously with testosterone and aromatase inhibitor, which suggests that conversion to estrogen is responsible for testosterone-mediated attenuation of atherosclerosis. Aortic nitric oxide release may be impaired in male estrogen-receptor knockout mouse [76] . In isolated coronary, femoral, and pulmonary arteries, testosterone showed a dose-dependent vasodilatory effect, caused by direct actions on vascular smooth muscle, via either potassium [77] or calcium channels [78] .
RELATIONSHIPS BETWEEN SERUM DEHYDRO-EPIANDROSTERONE SULFATE CONCENTRATION AND ATHEROSCLEROSIS
Decreased serum DHEA concentrations may be associated with increased risk of CVD in men. We evaluated relationships between serum DHEA-S concentration and carotid atherosclerosis in men with type 2 diabetes. Serum DHEA-S concentrations were measured in 206 consecutive men with type 2 diabetes. Serum DHEA-S concentration was associated negatively with carotid atherosclerosis determined by ultrasonographically evaluated IMT and plaque score in men with type 2 diabetes [79] .
Observational Studies
A few prospective clinical trials [80] , and some crosssectional studies [81] suggest that DHEA has a beneficial effect against development of atherosclerosis and/or its clinical manifestations in men. While DHEA is considered to have a protective effect against coronary artery disease and was found to inhibit atherosclerosis and plaque progression in an experimental model [82, 83] , some studies failed to find an association between decreased DHEA concentration and atherosclerosis [84, 85] .
Our study in men with type 2 diabetes demonstrated that serum DHEA-S concentrations were significantly lower in patients with than without CVD, in addition to finding a negative correlation of serum DHEA-S concentrations with ultrasonographically evaluated mean IMT and plaque score, which are early preclinical markers of atherosclerosis. Advanced age is one of the strongest predictors of coronary artery disease; a decline in DHEA concentration with age may partly explain age-related increases in risk of CVD.
Both light-to-moderate alcohol consumption and higher serum concentrations of DHEA are associated with reduced CVD mortality, raising the possibility of DHEA as a causal intermediate in the relationship between alcohol consumption and CVD. We therefore investigated relationships between alcohol consumption, serum DHEA-S concentration, and carotid atherosclerosis as evaluated by carotid ultrasonography in 404 consecutive men with type 2 diabetes [86] . Serum DHEA-S concentrations also were higher in light-to-moderate drinkers than in nondrinkers. Carotid IMT and plaque score were lower in light-to-moderate drinkers than in nondrinkers. We concluded that higher serum DHEA-S concentrations in light-to-moderate drinkers may represent part of the link between light-to-moderate alcohol consumption and lower CVD mortality.
As, both elevated urinary albumin excretion and low serum concentrations of DHEA are associated with increased CVD mortality [87] , DHEA might be a causal intermediate linking urinary albumin excretion to CVD. Accordingly, we investigated relationships of urinary albumin excretion to serum DHEA-S concentration in 357 consecutive men with type 2 diabetes [88] . Serum DHEA-S concentration correlated inversely with log (urinary albumin excretion), which suggests that serum DHEA-S concentration may represent part of the link between elevated urinary albumin excretion and higher CVD mortality in male patients with type 2 diabetes.
Interventional Studies
Clinical Studies
DHEA may exert its antiatherogenic action by several mechanisms: amelioration of insulin resistance, inhibition of differentiation and proliferation of smooth muscle cells and fibroblasts [89] ; a hypolipidemic effect [90] ; decreases in platelet aggregation [91] and in plasminogen activator inhibitor [43] ; and enhanced endothelial function [43] and vascular contractility [92] . DHEA also reduces atherogenic cytokines such as IL-6 [93] and TNF- [49] .
Low-dose DHEA supplementation (25 mg/day) was shown to improve vascular endothelial function. Flowmediated dilatation of brachial artery after transient occlusion, expressed as a percent change from the baseline arterial diameter, increased with DHEA supplementation in men with hypercholesterolemia [43] .
Because DHEA is metabolized enzymatically to both androgens and estrogens, whether DHEA exerts effects directly or only after conversion to androgens or to estrogens is not clear. However, DHEA has been shown to inhibit human vascular smooth muscle cell proliferation by mechanisms independent of either androgen or estrogen receptors [94] .
Animal Studies
Experimental studies [82, 83] suggest that DHEA could have a beneficial effect against development of atherosclerosis. Severe atherosclerosis was found in rabbits after aortic endothelial injury induced with a balloon catheter plus feeding a 2% cholesterol diet. However, rabbits additionally receiving DHEA showed almost a 50% reduction in plaque [83] . These beneficial actions were not attributable to differences in body weight gain, food intake, total plasma cholesterol, or distribution of cholesterol among VLDL, LDL, or HDL fractions. DHEA administration in a hypercholesterolemic rabbit model of heterotopic cardiac transplantation significantly retarded progression of accelerated atherosclerosis in both the transplanted heart and the native heart [82] .
CLINICAL IMPLICATIONS AND CONCLUSIONS
Because men with type 2 diabetes have relative hypogonadism [8, 9] , supplementation with androgen might reduce both insulin resistance and atherosclerosis. Evaluation of elderly men with physiologic testosterone deficiency are less clear-cut, and an appropriate biochemical cut-off below which replacement should be offered to such patients has not been clearly defined. Testosterone undecanoate and testosterone buciclate, which currently are undergoing evaluation for use in clinical practice, appear promising as longer-acting preparations providing a less variable testosterone concentration [63] . No current evidence suggests that androgen replacement in hypogonadal men causes an increase in prostate cancer, although studies addressing this issue have been small and retrospective. We suspect that both subphysiologic and supraphysiologic testosterone concentrations are likely to adversely affect insulin sensitivity. Weight loss in obese men has been shown to increase serum testosterone [95] . Life-style changes could be a logical first-line treatment in many ventrally obese men with andropause. Weight loss is important in prevention of progressive metabolic decompensation and CVD associated with obesity and the metabolic syndrome. While a number of preparations are available for testosterone replacement, little is known about suitability or efficacy of individual preparations for protection from insulin resistance or atherosclerosis. Long-term trials of testosterone replacement therapy also are needed to assess both efficacy and safety.
